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Abstract Alzheimer’s disease (AD) is a progressive and
incurable neurodegenerative disorder clinically character-
ized by cognitive decline involving loss of memory, rea-
soning and linguistic ability. The amyloid cascade
hypothesis holds that mismetabolism and aggregation of
neurotoxic amyloid-b (Ab) peptides, which are deposited
as amyloid plaques, are the central etiological events in
AD. Recent evidence from AD mouse models suggests that
blood-borne mononuclear phagocytes are capable of infil-
trating the brain and restricting b-amyloid plaques, thereby
limiting disease progression. These observations raise at
least three key questions: (1) what is the cell of origin for
macrophages in the AD brain, (2) do blood-borne macro-
phages impact the pathophysiology of AD and (3) could
these enigmatic cells be therapeutically targeted to curb
cerebral amyloidosis and thereby slow disease progression?
This review begins with a historical perspective of
peripheral mononuclear phagocytes in AD, and moves on
to critically consider the controversy surrounding their
identity as distinct from brain-resident microglia and their
potential impact on AD pathology.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia
in elderly populations throughout the world. With human
longevity increasing, AD prevalence is predicted to place
enormous strain on the public health system. Deposition of
amyloid-b (Ab) peptides [proteolytically derived from the
*110 kDa amyloid precursor protein (APP)] as b-amyloid
plaques within the brain is a defining feature of the disease
(Selkoe 2001). This age-dependent, insidious deposition of
b-amyloid is purported to cause an ‘‘amyloid cascade’’,
which results in a vicious feed-forward cycle, culminating
in neuronal death and dementia (Hardy and Allsop 1991;
Tanzi and Bertram 2005). A cure, effective treatment, or
preventative therapy for AD does not exist. Yet, a number
of studies in AD patients and in transgenic mouse models
of the disease have recently shown immune cell infiltrates
around Ab plaques. Collectively, these studies raise the
tantalizing possibility that a subset of bone marrow-derived
mononuclear phagocytes are capable of entering the brain
and potentially restricting cerebral amyloid.
During embryogenesis, hematopoietic myeloid cells
migrate into the brain and differentiate into microglia,
the resident central nervous system (CNS) macrophages
(Eglitis and Mezey 1997; Brazelton et al. 2000; Mezey
et al. 2000). Microglia continuously survey the CNS for
debris and foreign antigens, and thereby serve as a first line
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of immune defense in the brain and spinal cord. In the AD
brain and in transgenic AD mouse models, microglia
become activated in response to Ab deposits, and prolif-
erate and migrate to sites containing amyloid plaques
(Simard et al. 2006). In addition to these brain-resident
macrophages (referred to as microglia in this review),
a subset of innate immune cells also exist that are products
of pluripotent hematopoietic monocyte precursors. The
contribution of bone marrow-derived mononuclear phago-
cytes (used interchangeably with the term ‘‘peripheral
macrophages’’ in this review) to amyloid plaque-associated
microgliosis is still under debate, but is likely limited
(Wyss-Coray 2006; Ju¨cker and Heppner 2008). This is
because the potentially damaging effects of an inflamma-
tory immune response within the CNS are sanctioned by
the blood–brain barrier (BBB), which restricts passage of
substances and blood-borne cells (e.g., peripheral leuko-
cytes) into the brain (Wenkel et al. 2000).
Although the CNS has classically been regarded as an
immune privileged site, recent evidence indicates that
surveillance by peripheral leukocytes occurs both physio-
logically and during disease. It should be noted that
peripheral leukocyte traffic into the healthy CNS remains a
subject of debate, particularly with regard to surveillance T
cells. Although brain penetration of these cells is a quan-
titatively minor event, we nonetheless often detect CD4? T
cells in the brain parenchyma of unmanipulated healthy
wild-type mice (see Fig. 1). Yet, given that peripheral
immune cells are present in such small quantity within the
CNS, there is discussion over whether targeting them
would have a beneficial or detrimental impact on disease.
This debate may be moot when considering that peripheral
leukocytes can serve either productive or pathological roles
depending on the specific CNS disease (for a review, see
Rezai-Zadeh et al. 2009b). For example, exogenous leu-
kocytes have been shown to be pathogenic in diseases such
as experimental autoimmune encephalomyelitis (an animal
model for the human demyelinating disease multiple
sclerosis) (Fujinami and Oldstone 1985; Greter et al. 2005),
Parkinson’s disease (Czlonkowska et al. 2002; Whitton
2007) and human immunodeficiency virus encephalitis
(Petito et al. 2006; Liu et al. 2009). On the other hand,
infiltrating lymphocytes can serve to limit neuronal loss in
models of amyotrophic lateral sclerosis (Beers et al. 2008;
Chiu et al. 2008). Additionally, recent evidence from
mouse models supports the notion that infiltration of
peripheral mononuclear phagocytes limits progression of
AD pathology (Town et al. 2008) and militates against
West Nile virus encephalitis (Town et al. 2009). In the
context of AD and other neuroinflammatory diseases, a
critical understanding of the role of subpopulations of
microglia/macrophages is required to stimulate the right
cell type to eliminate toxic Ab and prevent neuronal
damage without bystander injury associated with neuroin-
flammation. Brain recruitment of exogenous leukocytes is
an intriguing strategy by which to protect and regenerate
the CNS (Yong and Rivest 2009). However, a thorough
understanding of the cellular and molecular mechanisms
responsible for trafficking of peripheral macrophages in
AD is crucial to efficiently coax these cells out of the
circulation and into the brain. In this article, we review (1)
the role of mononuclear phagocytes in the pathoetiology
and potential treatment of AD, (2) recent evidence that
points to a ‘‘blood-borne identity’’ of these cells, and (3)
controversies surrounding phenotypic distinction of these
cells from brain-intrinsic microglia.
A historical perspective
The longstanding debate surrounding the role of microglia/
macrophages in AD was initially ignited by landmark
studies in the late 1980s and early 1990s by Henryk
Wisniewski and Janusz Frackowiak. Wisniewski and Frac-
kowiak observed that microglia, while capable of engulfing
Ab in vitro, were not competent Ab phagocytes in vivo.
Using electron microscopy to examine the ultrastructure of
these enigmatic cells, Wisniewski noted that microglial
cells associated with Ab plaques in AD patient brains did
not contain Ab deposits within lysosomal compartments.
However, in the rare comorbidity of stroke with AD, brain-
infiltrating macrophages did contain lysosomal b-amyloid
fibrils (Wisniewski et al. 1989; Wisniewski et al. 1991;
Frackowiak et al. 1992). These observations led to the
Fig. 1 A confocal image of unmanipulated wild-type C57BL/6
mouse cerebral cortex showing presence of CD45?CD4? cells in
the parenchyma. Cortical layers are indicated by roman numerals and
individual channels are shown with DAPI nuclear counterstain
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conclusion that, while microglia did not have the ability to
clear Ab from the extracellular brain milieu, peripheral
macrophages could ‘‘home’’ to and remove Ab in vivo by
phagocytosis.
As with any important and thought-provoking work,
Wisniewski’s results sparked numerous questions. Was
there a true disparity between microglia and peripheral
macrophages regarding Ab clearance? Were infiltrating
macrophages capable of limiting cerebral amyloidosis?
Why were infiltrating macrophages restricted from the AD
brain in the absence of stroke comorbidity? Answering
these questions would prove difficult due to a number of
obstacles. For instance, aside from morphological differ-
ences, distinguishing between activated microglia and
macrophages can be complex as they share many of the
same cell surface receptors and signaling proteins. In fact,
despite the enlightening observations by Wisniewski et al.,
it would take nearly two decades for availability of modern
cellular and molecular biology techniques to address the
conditions under which peripheral macrophages were
capable of removing brain Ab.
The origin and role of mononuclear phagocytes
in the central nervous system
Around the time of Wisniewski’s observations, it was
understood that the CNS contained two distinct populations
of mononuclear phagocytes: the microglial cells of the brain
parenchyma and the macrophages that reside in perivascu-
lar spaces, meningeal folds, and the choroid plexus. These
two classes of phagocytes are known to differ in the pro-
duction of specific cytokines, cell surface immune antigen
expression, and ability to promote innate versus adaptive
immune responses. Despite these phenotypic differences,
there is mounting evidence that both classes of mononuclear
phagocytes share a common precursor. Microglia are
thought to originate from the yolk sac during embryogen-
esis, when macrophage progenitors (of blood-borne
monocytic origin) also exist. It is now generally accepted
that microglia originate from monocyte precursor cells that
migrate from the yolk sac into the developing CNS (Pessac
et al. 2001; Alliot et al. 1999). Furthermore, it is generally
thought that populations of microglia arise and are main-
tained entirely through local CNS proliferation (Ajami et al.
2007; Mildner et al. 2007). This conclusion has been
challenged, though, by important work demonstrating that
blood-borne monocyte progenitors can replenish pools of
parenchymal blood-borne macrophages and CNS-resident
microglia (Priller et al. 2001)—although this seems to only
occur to a limited extent.
Discrete populations of exogenous, blood-borne mono-
cytes are now believed to be recruited to the CNS, where
they traverse the BBB (primarily at post-capillary venules),
both normally and after CNS injury or disease. The fate of
these immune cells depends largely on the route taken to
brain infiltration. First, monocytes may only superficially
penetrate into the brain, and remain as perivascular mac-
rophages that are functionally distinct from brain-resident
microglia (Hawkes and McLaurin 2009). These cells may
migrate across the vascular wall where they enter the
perivascular space, meninges, or choroid plexus and dif-
ferentiate into tissue macrophages that closely resemble
brain-resident microglia. Finally, monocytes may progress
through the glia limitans (a network of astrocyte foot
processes) into the brain parenchyma and assume a bona
fide microglial phenotype. In a pioneering study, Priller
et al. demonstrated that hematopoietic cells are indeed
capable of entering the CNS and differentiating into
microglia. Utilizing irradiation chimeras in which donor
hematopoietic cells were genetically modified with a ret-
roviral vector encoding green fluorescent protein (GFP),
these researchers showed that marrow-derived cells are
capable of entering into the CNS and differentiating into
cells phenotypically resembling microglia. Additionally,
these GFP? microglia were found at sites of CNS damage,
underscoring the ability of blood-borne mononuclear cells
to migrate to sites of neuronal injury.
However, reports by Ajami, Mildner, and their col-
leagues have raised methodological concerns about studies
touting peripheral macrophage engraftment into the brain
after irradiation and bone marrow reconstitution. In an
elegant study, Ajami et al. used parabiosis (where the cir-
culatory systems of syngeneic mice are physically con-
nected) to generate chimeric animals. These parabiosis
experiments were conducted in parallel with conventional
irradiation/transplantation chimeras. Surprisingly, these
authors only found significant engraftment of GFP?
mononuclear cells in the CNS following irradiation (Ajami
et al. 2007). In another study, Mildner et al. demonstrated
that head-sparring irradiation resulted in relative exclusion
of marrow-derived GFP? mononuclear cells from the brain
parenchyma compared with conventional irradiation
chimeras (Mildner et al. 2007). These reports suggest that
full-body irradiation, by itself, causes damage to the BBB
that allows blood-borne mononuclear cells to more readily
traffic to and infiltrate both the healthy and injured CNS.
Furthermore, these authors concluded that local self-
renewal of microglia is sufficient to sustain brain-resident
mononuclear phagocyte populations, which they suggest
account for the bulk of CNS innate immune responses.
Yet, others have challenged that the studies by Ajami
and Mildner have their own technical limitations. For
example, the parabiosis model employed by Ajami et al.
has recently been found to underestimate constitutive
infiltration of mononuclear cells into lymphoid tissues (Liu
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et al. 2007). In addition, Mildner et al. did not detect
transplanted GFP? brain perivascular macrophages fol-
lowing head-sparring irradiation and bone marrow recon-
stitution, which is a well-established resident macrophage
subset. In light of these experimental pitfalls, the origin and
role of mononuclear phagocytes in CNS innate immunity
still remains to be fully elucidated.
Distinguishing between brain-resident microglia
and peripheral macrophages
The ability to distinguish cell type (microglia vs. mono-
cytes/macrophages) and provenance (CNS-resident vs.
blood-borne) of mononuclear phagocytes is critically
important in determining the functional roles of these cells.
As mentioned above, microglia and peripheral monocytes/
macrophages are phenotypically different and may also
display varying degrees of functional restriction. Accord-
ingly, differences in immunological/molecular marker
expression, morphological states, and functional charac-
teristics may be evaluated to discriminate between these
cellular subsets. In particular, quiescent microglia are
morphologically characterized by a small soma and rami-
fied processes, whereas, resting monocytes/macrophages
are rounded, oval, or amoeboid. However, the utility of
relying on morphological features to distinguish these cell
types is likely limited. For one, morphological assessment,
by its very nature, is qualitative. Further, a rapid phenotype
switch may occur after microglial activation, whereby cells
shorten their cellular processes and swell their soma,
thereby assuming an amoeboid morphology similar to
peripheral macrophages. Moreover, while resting macro-
phages are characterized by constitutive expression of
specific cell surface immune antigens including major
histocompatibility complex (MHC) class II, CD45, CD64,
CD68, CD86, and F4/80 antigen, microglia can be induced
to express these same markers following activation (Flaris
et al. 1993; Stoll and Jander 1999; Walker 1999). However,
CD45 expression on peripheral macrophages is generally
accepted to be higher than on activated microglia (Juedes
and Ruddle 2001), and so researchers often utilize flow
cytometry to distinguish between these two populations.
Functionally, resting populations of peripheral macro-
phages may be differentiated from populations of resting
microglia by constitutive secretion of interferon-c (IFN-c);
however, one group reported that the source of ‘‘macro-
phage’’ IFN-c production was actually emanating from
contaminating natural killer cells (Schleicher et al. 2005).
While these conventional means of discerning the identity
of mononuclear phagocytes are useful, they may not be
adequate for determining cellular lineage. In this regard,
expression levels of specific immunological markers such
as CD45, Ly-6C, Ly-6G, and the chemokine receptor
CCR2 on mononuclear phagocytes and their progenitors
may be relied upon, as these markers are reportedly present
when these cells migrate into the CNS (Drevets et al. 2004;
Sunderkotter et al. 2004; El Khoury et al. 2007; King et al.
2009). We recently utilized CD11c as a marker to distin-
guish peripheral macrophages (which express this surface
antigen) from brain-resident microglia (which are CD11c-
negative) (Town et al. 2008). Because we did not detect
CD11c expression by b-amyloid plaque-associated
microglia, we concluded that the low-level, chronic
inflammation that characterizes AD is not powerful enough
to elicit expression of this marker by brain-resident
microglia (which are constitutively negative for CD11c;
see Town et al. 2008). Possibly, CD11c expression by
brain-resident microglia requires strong, acute activation
(for example, in cases of CNS autoimmune disease such as
multiple sclerosis), and immunostimulation in the context
of AD is simply not vigorous enough. Altogether, these
various approaches for distinguishing mononuclear
phagocyte subsets have proven useful, but are nonetheless
limited as the ultimate phenotype and fate of these cells
after migration into the brain remains indeterminate.
Why target peripheral macrophages rather
than brain-resident microglia?
Wisniewski’s early findings prompted an intriguing ques-
tion: what makes peripheral macrophages more adept than
brain-resident microglia at phagocytosing Ab in vivo?
There are several characteristics of peripheral macrophages
that make them efficient professional Ab phagocytes. First,
monocyte precursors that develop into peripheral macro-
phages have a dynamic life cycle, while brain-resident
microglia have a prolonged lifespan and limited capacity to
divide (Graeber et al. 1992; Kennedy and Abkowitz 1998).
Further, it has been suggested that peripheral macrophages
can enter and exit the CNS compartment throughout life
(Dickson 1999). In contrast, microglia are permanent CNS
residents, and their phenotype is significantly influenced by
habitation there (Dickson 1999). Brain-resident microglia
are therefore more tightly regulated spatially and tempo-
rally, allowing for precise CNS-tuned immune responses
but restricted functional repertoire. In their quiescent
(resting) state, human brain-resident microglia in general
lack MHC-II (HLA-DR) antigen, cytokine expression,
CD45 antigen, and other surface immune molecules
required for antigen presentation and phagocytosis. Alter-
natively, peripheral mononuclear phagocytes constitutively
express HLA-DR and are capable of the full repertoire of
innate immune responses. Thus, while microglia serve as
sentinels to disruption of homeostasis in neural tissue and
964 D. Gate et al.
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have limited innate immune responses, peripheral mono-
nuclear phagocytes are unrestricted in their abilities to
engulf and digest cellular debris and pathogens.
Given that peripheral macrophages originate from
monocyte progenitors present in the bone marrow and the
circulation, these cells can be therapeutically targeted in
a minimally invasive fashion in the periphery (Rezai-
Zadeh et al. 2009a). Conversely, targeting brain-resident
microglia for therapeutics can be challenging due to the
presence of the BBB (Rezai-Zadeh et al. 2009b). More-
over, given the fact that peripheral macrophages are
generally regarded as professional phagocytes, they have
greater Ab phagocytic potential than their immune-
repressed microglia cousins. Consequently, although brain-
resident microglia and peripheral macrophages share the
same lineage, their phagocytic properties are strongly
determined by the microenvironment in which they reside.
Yet, a conspicuous and important question is whether the
provenance of the mononuclear phagocyte has functional
implications in the context of AD pathology. A recent report
from the laboratory of Mathias Ju¨cker has prompted the
iconoclastic conclusion that resident microglia don’t play
any significant role in Ab clearance (Grathwohl et al. 2009).
These researchers utilized a novel ‘‘suicide gene’’ trans-
genic mouse model, which expresses the herpes simplex
virus (HSV) thymidine kinase (TK) gene under regulatory
control of the myeloid-specific CD11b promoter (termed
CD11b-HSVTK mice). In principle, when these mice are
treated with the antiviral nucleotide analog prodrug ganci-
clovir (GCV), HSVTK (the suicide gene portion of the
system) converts the drug into a toxic triphosphate. Thus,
GCV treatment leads to selective ablation of proliferating
myeloid cells. After selectively ablating brain-resident
microglia in the APPPS1 transgenic mouse model of AD,
they found no effect on overall Ab burden, plaque mor-
phology, or distribution of cerebral Ab deposits. Addi-
tionally, these authors did not detect altered neural
dystrophy in these mice, suggesting that brain-resident
microglia are neither pathogenic nor remedial in regards to
Ab-driven neurotoxicity (Grathwohl et al. 2009).
These data further enforce the notion that microglia are
poor Ab phagocytes and do not significantly remodel Ab
plaques. However, others have challenged that this report
does not address the effect of GCV treatment on various
subsets of CD11b? cells in these mice, and that the short
time-course of microglial ablation (only a few weeks) begs
the question of whether these results are truly definitive.
Other critiques are that this report does not address the
percentage of ablation of the wide range of CD11b-
expressing cells of monocytic lineage nor whether subsets
are varyingly capable of restricting Ab burden. Moreover,
vascular toxicity and breakdown associated with GCV
treatment may complicate interpretation of these results.
Nonetheless, at face-value, these data imply that brain-
resident microglia are incapable of (1) phagocytosing/
clearing Ab from the parenchyma and (2) impacting neu-
ronal injury. If these results translate to the clinic, they
reinforce the notion that peripheral mononuclear phago-
cytes are a better pharmacological target for Ab clearance
than brain-resident microglia.
Yet, a recent report by Kiyota et al. has shed light on the
actions of microglia in the context of AD. These researchers
crossed a transgenic mouse model over-expressing che-
mokine (C–C motif) ligand 2 (CCL2) with the Tg2576
Alzheimer’s model. They reported that forced expression of
CCL2 enhanced microgliosis and induced diffuse amyloid
plaque deposition in Tg2576 mice. The authors’ interpre-
tation was that CCL2 and tumor necrosis factor-a directly
facilitated Ab uptake, intracellular Ab oligomerization, and
protein secretion (Kiyota et al. 2009). Therefore, while it is
becoming accepted that microglia are not potent Ab clear-
ing cells, their ability to remodel Ab plaques and contribute
to AD pathology requires further delineation.
Are infiltrating macrophages beneficial
or detrimental in AD?
The idea that the peripheral immune system could play a
beneficial role in mitigating AD pathology was initially
met with controversy and resistance. Early studies ques-
tioned whether: (1) blood-borne immune cells could be
manipulated to effectively traverse the BBB; (2) invasion
of peripheral immune cells into the brain would result in
beneficial phagocytosis of Ab deposits; and (3) such cells
would provoke deleterious brain inflammation and cause
tissue damage. The idea that blood-borne immune cells
might drive damaging brain inflammation is reasonable, as
a variety of CNS diseases earmarked by presence of
immune cell infiltrates are often accompanied by severe
inflammation and neuronal bystander injury.
In order to address whether bone marrow-derived cells
were capable of entering the CNS in response to Ab,
Stalder et al. generated a chimeric mouse model of AD in
which bone marrow-derived cells (but not resident
microglia) were selectively marked by GFP. In their model,
brain amyloid deposits triggered invasion of peripheral
macrophages. Importantly, GFP? peripheral macrophages
were much more likely to be found in the brain (associated
with amyloid) in mice expressing the APP23 transgene
than in wild-type animals (Stalder et al. 2005). However,
only a small subpopulation (less than 20%) of plaques were
associated with infiltrating macrophages, which called into
question the magnitude of peripheral macrophage entry
into the brain and the ability of these brain-invading cells
to respond to and/or clear Ab deposits. Moreover, the
Macrophages in Alzheimer’s disease 965
123
modest number of macrophage-associated Ab plaques
implied a brain-inhibitory mechanism or an intrinsic
peripheral macrophage defect in response to Ab. Although
the passage of peripheral mononuclear phagocytes into the
CNS seems limited, Serge Rivest’s group demonstrated
that bone marrow-derived cells that do succeed in tra-
versing the BBB display higher levels of proteins associ-
ated with antigen presentation than resident microglia
(Simard et al. 2006). These researchers utilized the afore-
mentioned transgenic mouse that expresses the TK protein
under the control of the CD11b promoter to demonstrate
that peripheral macrophages and not brain-resident
microglia have the ability to clear Ab by a phagocytic
mechanism. However, the model used included intracere-
broventricular injections and irradiation, both of which
potentially disrupt BBB integrity. Thus, the question of
whether disruption of the BBB is necessary for Ab phago-
cytic activity of invading macrophages still remains
controversial (Massengale et al. 2005). Nonetheless, the
findings of Simard et al. (2006) suggest that peripheral
immune cells may be more efficient Ab phagocytes than
resident microglia.
Two recent studies in mice indicate that, though limited,
the recruitment of blood-borne macrophages to Ab plaques
plays an important role. Joseph El Khoury and colleagues
crossed an AD mouse model with a strain that lacks the
CC-chemokine receptor 2 (Ccr2) gene. Interestingly, Ccr2
deficient mice displayed impaired trafficking of peripheral
macrophages and resident microglia to Ab plaques. More
importantly, however, this diminished recruitment of
mononuclear phagocytes was associated with increased Ab
plaque load and accelerated mortality (El Khoury et al.
2007). Additional studies by Michal Schwartz and col-
leagues provide further evidence for the importance of
peripheral macrophages in Ab plaque clearance. After first
observing that T cell based immunization augmented
clearance of Ab plaques by increasing the density of local
CD11c? dendritic-like cells (Butovsky et al. 2006), they
subsequently showed that this effect could be abrogated by
selective ablation of bone marrow-derived dendritic cells
(Butovsky et al. 2007). These studies further indicate that
brain invasion of peripheral immune cells may play an
important role in reducing Ab burden and associated cog-
nitive impairment. However, more work needs to be done
to understand mechanisms of blood-borne phagocyte
recruitment to the brain before we can design effective
therapeutic strategies to coax these cells across the BBB.
Recent studies by our group illuminated a novel approach
to this problem. We found that interruption of transforming
growth factor beta (TGF-b) and downstream Smad2/3 sig-
naling (TGF-b-Smad2/3) in innate immune cells in a mouse
model of AD significantly diminished cerebral amyloid
burden and partially remediated behavioral impairment
(Town et al. 2008). Importantly, this effect was associated
with recruitment of blood-borne macrophages to Ab
deposits, and further in vitro mechanistic investigation
revealed that peripheral macrophages, but not microglia,
displayed increased Ab phagocytosis in this scenario. Fur-
thermore, these brain-infiltrating macrophages resembled a
subset of peripheral mononuclear phagocytes shown to
display an anti-inflammatory (Ly-6C-) profile (Sunderkot-
ter et al. 2004; Geissmann et al. 2003). Thus, our results
show that removing immunosuppressive TGF-b signaling
from blood-borne macrophages effectively recruits these
cells to brain amyloid deposits. Importantly, this beneficial
response on restricting cerebral amyloid does not come at
the cost of increased brain inflammation, since these animals
had increased brain interleukin (IL)-10 mRNA abundance.
If these results translate to the clinical syndrome, then these
peripheral phagocytes may be therapeutically targeted for
both anti-inflammatory and pro-Ab phagocytic outcomes
(Town et al. 2008; Town 2009).
Peripheral macrophages may not necessarily need to
cross the BBB to exert beneficial effects on AD. Up to 86%
of human AD cases present with cerebral amyloid angi-
opathy (CAA) (Ellis et al. 1996), characterized by depo-
sition of Ab in cerebral vessels (Jellinger and Attems
2008). Importantly, CAA severity correlates with degree of
dementia in humans (Attems et al. 2005), although there
has been much debate about whether CAA is a driving
force in the pathobiology of AD. Yet, CAA may represent
an important therapeutic target in AD. Recently, Hawkes
and McLaurin showed that a perivascular subset of
peripheral macrophages are important for clearance of
CAA (Hawkes and McLaurin 2009). They observed that
macrophage-depleted TgCRND8 mice exhibited signifi-
cantly more evidence of cerebral vascular Ab deposits
(comprised of the more toxic Ab42 peptide) compared to
vehicle controls. This group further noted that stimulating
peripheral mononuclear phagocyte turnover via chitin
treatment resolved CAA, an effect that appeared to be
specifically mediated by peripheral mononuclear phago-
cytes as opposed to activated microglia or reactive astro-
cytes. Thus, this previously underappreciated perivascular
macrophage subset may hold therapeutic potential for
efficient clearance of vascular Ab deposits.
Can pro-inflammatory macrophages be beneficial
in AD?
Blood-borne mononuclear cells consist of heterogeneous
populations of effector macrophages. It is now generally
accepted that at least two effector macrophage subsets can
be classified based on functional differences. The so-called
M1 macrophages are short-lived and are thought to be
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actively recruited to inflamed tissues, where they elicit pro-
inflammatory innate immune responses. Alternately, M2
macrophages are recruited to non-inflamed tissues and are
believed to be highly phagocytic, anti-inflammatory
effector cells (Geissmann et al. 2003; Rauh et al. 2005;
Colton 2009). Although initially thought to be epiphe-
nomenon, it is now generally accepted that neuroinflam-
mation is intimately involved in the pathogenesis of AD.
For this reason, anti-inflammatory strategies have been
touted as potential therapeutic interventions for AD. Along
these lines, our studies have demonstrated that infiltrating
anti-inflammatory (M2-like) cells facilitate Ab clearance
(Town et al. 2008). However, it remains to be determined if
all types of neuroinflammatory responses are inherently
detrimental in neurodegenerative diseases including AD;
some forms of brain inflammation may actually be
beneficial.
The significance of this hypothesis is accentuated by
recent studies, which showed that sustained recruitment of
peripheral immune cells across the BBB was not only
associated with neuroinflammation, but actually decreased
cerebral amyloid burden (Shaftel et al. 2007a; Shaftel et al.
2007b). Using the IL-1bXAT transgenic mouse model,
Shaftel et al. forced expression of IL-1b in the hippocam-
pus, and observed persistent infiltration of diverse leukocyte
populations. Importantly, this sustained invasion of
peripheral immune cells did not evoke overt neurotoxicity.
Shaftel et al. then crossed transgenic IL-1bXAT mice with
the Alzheimer’s APP/PS1 mouse model, thereby triggering
unilateral overexpression of IL-1b in the hippocampus and
driving sustained neuroinflammation in an AD mouse
model. Surprisingly, this neuroinflammatory response
resulted in reduced cerebral amyloid pathology. The pro-
posed mechanism for this result was that a subpopulation of
mononuclear phagocytes was recruited to amyloid plaques
and cleared them. This response seems to have been driven
by bone marrow-derived macrophages, and one interpreta-
tion of their findings is that a strong brain inflammatory
response induces infiltration of peripheral M1-like mono-
nuclear cells that restrict cerebral amyloidosis.
A recent report by Pritam Das and coworkers further
elucidated the beneficial role of a pro-inflammatory
Fig. 2 A schematic representation showing the roles of mononuclear
phagocytes in Alzheimer’s disease. A penetrating cerebral artery is
shown on the left, and a b-amyloid plaque within the brain
parenchyma is shown to the right. Peripheral mononuclear phago-
cytes (macrophages) are infiltrating the brain parenchyma and homing
to the b-amyloid plaque, where they phagocytose and clear deposited
Ab. Peripheral mononuclear phagocytes are depicted in green, brain-
resident microglia are magenta, neurons are blue, and the b-amyloid
plaque is shown in red
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response in the context of AD. These researchers utilized a
mouse model in which the murine form of the pleiotropic
proinflammatory cytokine IL-6 (mIL-6) was overexpressed
in brains of AD model mice, including TgCRND8 and
Tg2576 animals. IL-6 has been purported to have a path-
ogenic role in AD because it is upregulated in the plasma,
cerebrospinal fluid, and brain parenchyma of AD patients
and is expressed at Ab plaques (Licastro et al. 2000; Huell
et al. 1995). As predicted, murine IL-6 expression pro-
moted widespread gliosis in these AD mouse models. What
was completely unexpected was that overexpression of this
pro-inflammatory cytokine reduced Ab deposition in
TgCRND8 mice. Further, the researchers noted significant
up-regulation of glial phagocytic markers in vivo and an
increase in microglia-mediated phagocytosis of Ab aggre-
gates in vitro. Murine IL-6 expression did not affect APP
processing in TgCRND8 mice, nor were differences
detected in APP processing or steady-state levels of Ab in
young Tg2576 animals (Chakrabarty et al. 2010). Although
the contribution of peripheral, bone marrow-derived mac-
rophages to Ab clearance was not specifically investigated,
these data further suggest that at least this particular form
of microglial activation may be beneficial by enhancing Ab
plaque clearance. These results are accentuated by a recent
report by Boissonneault et al., who demonstrated that
systemic macrophage colony-stimulating factor adminis-
tration is a powerful treatment to stimulate bone marrow-
derived microglia, degrade Ab and prevent cognitive
decline associated with cerebral amyloidosis in the
Alzheimer’s APP/PS1 mouse model (Boissonneault et al.
2009). However, one must not overlook the potentially
devastating effects of runaway brain inflammation in the
context of AD. This is underscored by recent suspension of
the Elan/Wyeth AN-1792 Ab immunotherapy trial, which
resulted in life-threatning adverse events including severe
brain inflammation (aseptic meningoencephalitis) in *6%
of treated patients (Nicoll et al. 2003; Town et al. 2005;
Holmes et al. 2008).
Concluding remarks
Over two decades ago, Henryk Wisniewski made a seminal
observation. He found that, while brain-resident microglia
were ‘‘frustrated phagocytes’’ that were unable to clear
cerebral amyloid; blood-borne macrophages present in the
brain parenchyma of stroke patients with AD had Ab
clearance aptitude. It would take over 20 years and the
advent of modern cellular and molecular biology for us to
begin to understand this innate immune cell dichotomy
(Fig. 2). Even so, we have only just begun to address
questions surrounding these enigmatic cells. For example,
which subset(s) of peripheral mononuclear phagocytes are
most efficient at clearing cerebral amyloid? How do we
target these professional phagocytes to remove Ab without
incurring bystander injury associated with inflammation?
On the translational medicine front, we are just now
exploring genetic and pharmacologic strategies to promote
brain entry of peripheral mononuclear phagocytes with the
goal of restricting cerebral amyloid. The 5-year view looks
promising as we invest in answering these and other tan-
talizing questions about this potentially promising cell type
to target for the treatment of AD.
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